ArticleEuropean journal of neurology2025
Cannabis and Cognitive Function in Multiple Sclerosis: Findings From a Large Consecutive Clinical Sample.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The non-linear relationship between self-reported cognitive concerns and performance-based cognitive dysfunction in people with multiple sclerosis: a cross-sectional study.Journal of neurology · 2026Article
- Cannabis and Cognitive Function in Multiple Sclerosis: Findings From a Large Consecutive Clinical Sample.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCannabis is commonly used in persons with MS (pwMS) for symptom relief. Previous studies investigating the effects of cannabis on objective cognitive functioning in MS have yielded mixed results.
aimTo examine associations of recreational cannabis use with objective cognitive performance in a large, consecutive clinical sample of pwMS.
methodsIn a cross-sectional study, 847 pwMS provided information on cannabis consumption and were administered the Minimal Assessment of Cognitive Function in MS (MACFIMS) battery, assessing memory, executive function, language, and processing speed. Cognitive performance of cannabis users (N = 254) and nonusers (N = 593) was compared by means of a one-way MANOVA. Multiple linear regressions then examined whether cannabis use independently predicted cognitive test results.
resultsA significant effect of cannabis use on cognitive performance was observed, F(11, 692) = 1.955, p = 0.030, Wilks λ = 0.970, with users performing significantly poorer than nonusers on the SDMT [F(1, 703) = 6.099, p = 0.014]. Regression models, taking into account covariates (age, education, disease duration, anxiety, and fatigue) revealed that cannabis independently predicted performance on the SDMT, PASAT-3, and PASAT-2, all p < 0.001. Models explained 15.8%, 7.1%, and 8.7% of variance, respectively.
conclusionThis cross-sectional study provides evidence that cannabis use is associated with poorer processing speed and working memory in pwMS, thereby presenting a possible additional risk factor for cognitive impairment. This finding takes on added concern in light of cannabis use increasing with its legalization, and the worldwide increase of cannabis potency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.